Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Acumen Pharmaceuticals reports robust Q4 earnings, ACU193 progress promising

Acumen Pharmaceuticals showcased strong financials and progress with ACU193 in their Q4 2022 earnings call. While facing challenges related to dosing strategies and commercial implications, the company is well-positioned to capitalize on opportunities for further development and market success.

Acumen Pharmaceuticals reports robust Q1 performance and advances Alzheimer's program

Acumen Pharmaceuticals demonstrates strong financial stability and progress in their Alzheimer's program.
Strategic focus on target engagement and dose selection enhances the clinical development pathway for ACU193.
Challenges lie in managing trial scenarios, but opportunities exist in data insights and regulatory interactions.

Acumen Pharmaceuticals reports positive Phase I results and solid financial standing

Acumen Pharmaceuticals showcased promising results for ACU193 in early Alzheimer's treatment and maintained a strong financial position with ample runway for future activities.
While facing challenges in dose selection and fundraising needs, the company has opportunities to advance drug development and explore innovative dosing methods.

Acumen Pharmaceuticals reports Q3 loss but advances Alzheimer's treatment

Acumen Pharmaceuticals showcased positive advancements in ACU193 with promising CSF biomarker results, despite reporting a loss from operations in Q3.
The company's strong financial position, highlighted by $282.7 million in cash and a new credit facility, supports ongoing research and development efforts.
Addressing operational challenges and seizing opportunities in refining treatment approaches and study timelines are crucial for Acumen Pharmaceuticals' future success.

Acumen Pharmaceuticals reports positive Phase I results for Alzheimer's treatment

Acumen Pharmaceuticals showcased progress in sabirnetug development, facing challenges in study design and dosing strategies while aiming to capitalize on therapeutic opportunities for Alzheimer's treatment.

Acumen Pharmaceuticals reports Q1 loss, progresses ALTITUDE study

Acumen Pharmaceuticals faces challenges in R&D expenses and logistical integration but shows strength in collaborations and enrollment progress.
Opportunities lie in diversification through new studies and potential incorporation of formulations into ongoing trials.
Overall, the company's financials and strategic focus indicate progress and commitment to advancing drug development.

Acumen Pharmaceuticals advances Alzheimer's treatment with strong financial backing

Acumen Pharmaceuticals is on track with the development of sabirnetug, backed by strong financials and a clear strategy to address Alzheimer's disease. While facing enrollment and market challenges, the company's upcoming R&D Day could unlock new opportunities for growth and innovation.

Acumen Pharmaceuticals reports progress in Alzheimer's treatment development and financial stability

Acumen Pharmaceuticals is making significant progress in its clinical efforts for sabirnetug, with faster-than-expected enrollment in the Phase II study.
The company's financial stability, highlighted by $259 million in cash and marketable securities, supports ongoing research and development initiatives.
Challenges in managing R&D expenses and addressing analyst inquiries underscore the complexities and opportunities in advancing Alzheimer's treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today reported financial results for the third quarter of 2022 and provided a business update.

Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease, today announced that the Company will report its financial results for the third quarter 2022 on Monday, November 14, 2022. The Company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.

Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022

Athira Pharma

Anavex Life Sciences

Biogen

BioVie Inc

Eli Lilly

Prothena

Roche Holding AG

Cassava Sciences Inc

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.

Trading Ideas On The Upcoming CTAD 2022 Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs), has been granted Fast Track designation for the treatment of early Alzheimer's disease by the U.S. Food and Drug Administration (FDA). ACU193 is currently being studied in the Phase 1 INTERCEPT-AD trial designed to assess safety and proof of mechanism of ACU193.

Acumen's ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease

Akero Therapeutics Inc

FaZe Holdings Inc

Forge Global Holdings Inc

Grove Collaborative Holdings

Immuneering Corp

Novavax

Value Line

Ventyx Biosciences

Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.

These Are the Five Best and Worst Performing Small-cap Stocks in September 2022

Source: pathdoc / Shutterstock.com Acumen Pharmaceuticals (NASDAQ: ABOS ) stock is rocketing higher on Wednesday but it's not due to any news from the company. Instead, investors have Biogen (NASDAQ: BIIB ) to thank for the increase of ABOS stock's price.

Why Is Acumen (ABOS) Stock Up 95% Today?

Alzamend Neuro

Ginkgo Bioworks Holdings

NeuroSense Therapeutics Ltd

Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants John Woolford - Investor Relations, Westwicke Daniel O'Connell - President & Chief Executive Officer Eric Siemers - Chief Medical Officer Matt Zuga - Chief Financial Officer & Chief Business Officer Conference Call Participants Judah Frommer - Credit Suisse Tom Shrader - BTIG Ting Liu - UBS Operator Good day. Thank you for standing by, and welcome to the Acumen Pharmaceuticals, Second Quarter 2022 Update Call.

Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q2 2022 Results - Earnings Call Transcript

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 15, 2022 (GLOBE NEWSWIRE) --  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease, today reported financial results for the quarter ended June 30, 2022 and provided a business update.

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the Company will report its financial results for the second quarter 2022 on Monday, August 15, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.

Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022

Model designed to fill need for soluble amyloid beta oligomer reference standards in bioanalytical assays Model designed to fill need for soluble amyloid beta oligomer reference standards in bioanalytical assays

Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer's disease

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the company will participate in the following upcoming conferences:

Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants John Woolford - IR, Westwicke Daniel O'Connell - President & CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Operator Operator Thank you for standing by, and welcome to the Acumen Pharmaceuticals, First Quarter 2022 Update Call. At this time, all participants are in a listen-only mode.

Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q1 2022 Results - Earnings Call Transcript

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 16, 2022 (GLOBE NEWSWIRE) --  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today reported financial results for the quarter ended March 31, 2022 and provided a business update.

Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 11, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the company will report its financial results for the first quarter 2022 on Monday, May 16, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.

Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022

Acumen focused on developing investigational monoclonal antibody targeting amyloid beta oligomers Acumen focused on developing investigational monoclonal antibody targeting amyloid beta oligomers

Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals' New Approach to Treating Alzheimer's Disease

Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q4 2021 Results - Earnings Call Transcript

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 28, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today reported financial results for the full year ended December 31, 2021, and provided recent business highlights.

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the company will report its financial results for the fourth quarter and full year 2021 on Monday, March 28, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.

Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today reported financial results for the quarter ended September 30, 2021 and provided recent business highlights.

Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today reported financial results for the quarter ended June 30, 2021 and provided recent business highlights.

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights

Ames National

German American Bancorp

Simon Property Group

According to the Insider Cluster Buys Screen, a Premium feature of Gurus, five stocks with high number of unique insider buys during the past month include German American Bancorp Inc. ( GABC , Financial), Simon Property Group Inc. ( SPG , Financial), Partners Bancorp ( PTRS , Financial), Ames National Corp. ( ATLO , Financial) and Acumen Pharmaceuticals Inc. ( ABOS , Financial).

5 Stocks With High Insider Cluster Buys During July

Krispy Kreme

Torrid Holdings

EverCommerce

D-MARKET Electronic Services

The Glimpse Group

Acumen Pharmaceuticals, D-MARKET Electronic Services & Trading, Evercommerce, Torrid Holdings, and the Glimpse Group will also make their debuts.

Krispy Kreme and 5 Other IPOs to Begin Trading

Acumen Pharmaceuticals Inc. shares soared 25% in their trading debut Thursday, after the biotech's initial public offering priced at the high end of its proposed range. Acumen sold 10 million shares at $16 a share to raise $160 million.

Acumen Pharmaceuticals shares soar 25% in trading debut

CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes to be a key underlying cause of Alzheimer's disease, today announced the pricing of its upsized initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to Acumen, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $160 million. All of the shares of common stock are being offered by Acumen. In addition, Acumen has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

News for Acumen Pharmaceuticals Stock (ABOS)